Research Article: An exploratory clinical study of ?-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma
Abstract:
Background: ?-glucan has been reported to be a potential natural immune modulator for tumor growth inhibition. We aimed to evaluate the efficacy and safety of ?-glucan plus immunotherapy and chemotherapy in the first-line treatment of advanced gastric adenocarcinoma.
No summary available.